Although MAPK acts downstream of different pathways, MEK inhibition seems to have a more pronounced pro-apoptotic efficacy in prostate cancer models with ERK1/2 activation, like DU145 and 22Rv1 cells. This evidence concerns the gene MAPK3 and prostate carcinoma.